Two-year results from ARC004, a follow-on study to phase 3 PALISADE trial of Palforzia (peanut allergen powder) in patients with peanut allergy

After 2-years of daily treatment with Palforzia, more than 80% of patients undergoing the food challenge demonstrated desensitisation to 2000 mg peanut protein (equivalent to ~14 peanut kernels). Desensitization rates were higher in daily vs. non-daily dosing groups

SPS commentary:

Palforzia was approved by the FDA in January 2020 as an oral immunotherapy for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy. In Europe, a marketing authorisation application is under review with the European Medicines Agency.


Biospace Inc.